sle and pulmonary hypertension

Systemic Lupus Erythematosus (SLE) is an autoimmune disorder that can lead to Pulmonary Artery Hypertension (PAH), a severe complication that may result in right-sided heart failure and mortality. PAH is characterized by elevated pressures within the pulmonary arteries, necessitating increased effort from the heart to circulate blood through the lungs. Untreated, this condition can be life-threatening.

Symptoms of PAH in SLE patients may include shortness of breath, fatigue, chest pain, and fainting. These symptoms can intensify as the disease advances. The diagnosis of PAH typically involves a battery of tests, such as electrocardiograms, echocardiograms, chest X-rays, and pulmonary function tests. Once confirmed, treatment often includes medications to reduce blood pressure and enhance cardiac function, in addition to therapies targeting the underlying SLE.

For SLE patients at risk of developing PAH, regular medical evaluations and vigilant monitoring of any new or exacerbating symptoms are crucial. Immediate medical attention is advised if symptoms like difficulty breathing, chest pain, or others potentially linked to PAH emerge. Treatment should be administered under a physician's supervision, and patients should not alter medication dosages or discontinue treatment without professional guidance.